Novo Nordisk Foundation Establishes Major European Obesity Research Initiative

The Novo Nordisk Foundation has committed DKK 450 million (approximately $60 million USD) to a new six-year pan-European research program called CardioMetabolic Bridge. This initiative aims to bolster academic research and facilitate company formation across Europe, with initial hubs in key cities. The program is designed to accelerate early-stage scientific discoveries and channel promising drug candidates into Novo Nordisk's future development pipeline.